89020-94-0

Basic information

• Product Name: 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-[(trifluoromethyl)thio]phenyl]-
• CAS NO: 89020-94-0
• Molecular Formula: C12H11F3N2O2S
• Molecular Weight: 304.293
• Mol File: 89020-94-0.mol

Chemical Properties

• CAS DataBase Reference: 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-[(trifluoromethyl)thio]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-[(trifluoromethyl)thio]phenyl]-(89020-94-0)
• EPA Substance Registry System: 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-[(trifluoromethyl)thio]phenyl]-(89020-94-0)

Safety Data

• Hazardous Substances Data: 89020-94-0(Hazardous Substances Data)

Upstream product

• 13257-67-5 2-amino-2-methylpropionic acid methyl ester 
• 24032-84-6 4-(Trifluoromethylthio)phenyl isocyanate 
• 17288-15-2 ethyl 2-aminoisobutyrate hydrochloride 
• 15028-41-8 methyl 2-aminoisobutyrate hydrochloride 

Downstream Products

• 945257-67-0 1-[(2-chloropyridin-4-yl)methyl]-5,5-dimethyl-3-{4-[(trifluoromethyl)thio]phenyl}imidazolidine-2,4-dione 
• 945103-96-8 5,5-dimethyl-3-{3-nitro-4-[(trifluoromethyl)thio]phenyl}imidazolidine-2,4-dione 

Relevant articles and documents

Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: Advantages in comparison with competitive inhibitors

A new series of IGF-1R inhibitors related to hydantoins were identified from a lead originating from HTS. Their noncompetitive property as well as their slow binding characteristics provided a series of compounds with unique selectivity and excellent cellular activities.

Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

Compounds of formula (I): wherein Ra, Rb, R, X1 and X2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

The disclosure relates to compounds of formula (I): wherein Ra, Rb, R, and n are as defined in the disclosure, to pharmaceutical compositions comprising said compounds, and to processes for making and methods of using the same.

Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.